Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
Liver DiseaseFungal Infection
Interventions
DRUG

Anidulafungin

Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.

DRUG

Liposomal amphotericin B

Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.

Trial Locations (12)

Unknown

Hospital Reina Sofia, Córdoba

Complexo Hospitalario de A Coruña, A Coruña

Hospital Clinic i Provincial, Barcelona

Hospital de Bellvitge, Barcelona

Hospital Vall d'Hebrón, Barcelona

Hospital de Cruces, Bilbao

Hospital Doce de Octubre, Madrid

Hospital Gregorio Marañón, Madrid

Hospital Ramón y Cajal, Madrid

Hospital Carlos Haya, Málaga

Hospital Central de Asturias, Oviedo

Hospital Marqués de Valdecilla, Santander

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Fundacion SEIMC-GESIDA

OTHER

NCT01303549 - Anidulafungin vs Amphotericin B Safety in High Risk Hepatic Transplant Recipients | Biotech Hunter | Biotech Hunter